CYTK · Cytokinetics, Incorporated
$61.23
-1.76% last session
End-of-day data · close of 2026-10-23
Market cap
$9B
Enterprise value
$9B
Trailing P/E
—
Forward P/E
-13.7
Dividend yield
0.0%
Beta
0.41
Avg volume
2M
Employees
1K
Daily Change %
-1.76%
5 Days Change
0.61%
10 Days Change
1.15%
30 Days Change
-5.29%
60 Days Change
-19.15%
Month to Day Change
-5.01%
Year to Day Change
-1.90%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — CYTK
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-19
Latest call per bank · past 12 months
RBC Capital
Outperform$113
+84.6% vs priceBarclays
Overweight$110
+79.7% vs priceJP Morgan
Overweight$103
+68.2% vs priceUBS
Buy$115
+87.8% vs priceCitigroup
Buy$99.00
+61.7% vs priceWells Fargo
Overweight$105
+71.5% vs priceMorgan Stanley
Overweight$103
+68.2% vs priceGoldman Sachs
Buy$95.00
+55.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | HC Wainwright & Co. | Reiterates | Buy | $140 |
| 2026-10-16 | William Blair | Initiates | Outperform | $0.00 |
| 2026-10-08 | RBC Capital | Maintains | Outperform | $112 → $113 |
| 2026-08-31 | HC Wainwright & Co. | Reiterates | Buy | $140 |
| 2026-08-13 | Barclays | Maintains | Overweight | $95.00 → $110 |
| 2026-08-13 | JP Morgan | Maintains | Overweight | $97.00 → $103 |
| 2026-08-10 | Truist Securities | Maintains | Buy | $106 → $112 |
| 2026-08-07 | RBC Capital | Maintains | Outperform | $117 → $112 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 36 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 11.2% below the 50-day MA ($68.92).
- bearish: Price vs 200-day MA: Trading 12.7% below the 200-day MA ($70.12).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.30) — short-term momentum is improving.
- bearish: 52-week range: Price is within 10% of the 52-week low ($57.50).
CYTK Price Chart
Loading chart for CYTK…
Fundamentals
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.